# 신약개발을 위한 약물대사

한국화학연구원

**Drug discovery - Pre-clinical - Clinical trials - Regulatory approval**

현재 drug approval pipeline : 평균적으로 15년, 5000~10000 compounds 중 하나

Dose-Effect relationship : Pharmacokinetics & Pharmacodynamics

Clinical safety, Efficacy, **PK/bioavailability**(good PK는 target site의 충분한 노출 기간 제공)

- Pharmacoinetic characterization via time v/s concentration profile
    
    **PK**는 drug ADME properties를 위한 mathematical descriptor (from time-concentration data). 
    
    absorption distribution 계산 → BUT 비용이 많이 든다 → 효율적인 Drug discovery 과정 거쳐야 함!
    

Drug elimination : 대부분 **metabolism**(by lung)에 의해서 이루어진다.

lung 외에도 hepatic, intestine, kidney 등에 의해서도 eliminate됨.

그 외에도 urinary excretion, biliary excretion 등에 의해 소실 가능.

Drug clearance → total exposure / T(1/2)

- Drug metabolism in drug elimination route

**In vitro systems to study metabolism**

1) Livertissue(Liver Microsome)

2) S9 Fraction : contains both phase 1, 2 enzymes

Homogenize / Low speed centrifugation 

3) Cytosolic Fraction + Microsomal Fraction

cytosol : contains soluble phase2 enzymes / high speed centrifugation

**→ Microsomal fraction 이용!**

**Metabolism based drug-drug interaction** : 동일 약물대사효소를 대상으로 2가지 이상의 약물의 경쟁작용에 의해 기인

- 해당 enzyme에 대해 **substrate / inhibition / induction(inducers)**
    
    inhibition : 기질 약물 대사의 지연 → 기질 약물 혈중 농도 증가
    
    induction : 기질 약물 대사의 유도 → 기질 약물 혈중 농도 감소
    
- 최적의 혈중 농도는 개발 과정에서 정해진다.
- Drug interaction studies에 대해 EMA, FDA 등에서는 guidance 제공
    
    **Safety Testing of Drug Metabolites - Guidance for Industry(FDA)**
    
    ex) 비만 치료제로 쓰이는 R483(dose) 중단
    

→ 초기부터 대사 안정성이 높은 물질을 선별하는 것이 효율적!

**Drug metabolic reactions**

목표 : Drug → More polar(water soluble) drug with metabolism

- **Phase I** : functionalization
    
    parent drug를 더 polar metabolite로 변환.
    
    by introducing/unmasking a functional groups
    
    enzyme ex : **P450**, AO, FMO, MAO, CE - **CYP3A4**/5/7 대부분
    
    - **reaction** : oxidation, reduction, hydrolysis

- **Phase II** : Conjugation(subsequent) reactions
    
    enzyme ex : UGT, SULT, GST, NAT - UGT 대부분
    
    - **reaction** : glucuronidation, acetylation, sulfation

ADME barriers : Dose부터 Target까지 Absorption, Metabolism, Excretion, Distribution 등의 방해 요소 존재

## 약물의 대사 안정성

- 대사 안정성 실험을 통한 데이터의 생성
- 대사 안정성 예측 모델

### Approaches to improve stability

(Kumar, G.N. and S.Surapaneni, Role of drug metabolism in drug discovery and development. Medicinal research reviews, 2021. 21(5))

- Introducing isosteric groups
- Cyclisation
- Introducing heteroatoms
- Incorporating halogenatom / Change in attachedring size / Deuteriation / Changing chirality

Metabolic stability assay

- single point assay
    - high-throughput : useful in early discovery to spot issues an rank-order compounds
    - use microsomes from different species-can spot species-difference
    - fraction of unchanged drug after 30 min(%remaining)로 read out
- half-life assay
    - low-throughput but much more useful in calculating CL(int) and thus predicting in vivo clearance
    - K(el), T(1/2), CL(int)로 read out

**Classification of *in vitro* metabolic stability**

**→ By remaining after 30 min, T(1/2), intrinsic clearance**

### AI driven drug discovery

- 2020 초반 : Exscientia가 human clinical trials를 위한 first-ever-AI-designed drug molecule 발표
- 2021.7 : DeepMind의 AlphaFold AI system 발표
    
    predict protein structures / AlphaFold Protein Structure Database 존재
    
- 2023.1 : AbSci가 생성형 AI를 사용하여 “to create and validate de novo antibodies in silico”

**Case study : Computational models to predict metabolic stability**

→ 한국화학연구원 : PredMS

(이미지 참고)

### Advances in the prediction of metabolic stability

(Renn, A, Su, B-H, Liu, H, Sun, J, Tseng, YJ. Advanced in the prediction of mouse liver microsomal studies : From machine elarning to deep learning. WIREs Comput Mol Sci.2021)

### Importance of data curation

(Data Curation can improve the prediction accuracy of metabolic intrinsic clearance, molinf)